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Abstract
The effect of intra-aortic balloon counterpulsation (IABC) varies, and it is unknown whether this is due to a heteroge-
neous coronary physiological response. This study aimed to characterise the coronary and left ventricular (LV) effects of
IABC and define responders in terms of their invasive physiology. Twenty-seven patients (LVEF 31 ± 9%) underwent
coronary pressure and Doppler flow measurements in the target vessel and acquisition of LV pressure volume loops after
IABC supported PCI, with and without IABC assistance. Through coronary wave intensity analysis, perfusion efficiency
(PE) was calculated as the proportion of total wave energy comprised of accelerating waves, with responders defined as
those with an increase in PE with IABC. The myocardial supply/demand ratio was defined as the ratio between coronary
flow and LV pressure volume area (PVA). Responders (44.4%) were more likely to have undergone complex PCI (p =
0.03) with a higher pre-PCI disease burden (p = 0.02) and had lower unassisted mean arterial (87.4 ± 11.0 vs. 77.8 ±
11.6 mmHg, p = 0.04) and distal coronary pressures (88.0 ± 11.0 vs. 71.6 ± 12.4 mmHg, p < 0.001). There was no effect
overall of IABC on the myocardial supply/demand ratio (p = 0.34). IABC has minimal effect on demand, but there is
marked heterogeneity in the coronary response to IABC, with the greatest response observed in those patients with the
most disordered autoregulation.
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Introduction
Intra-aortic balloon counterpulsation (IABC) is still the most
commonly used percutaneous cardiac assist device, employed
for a variety of different indications such as myocardial pro-
tection during high-risk percutaneous coronary intervention
(PCI) and treatment of cardiogenic shock. Despite decades
of observational data suggesting physiological benefit [1–4],
randomised controlled trials (RCT) have failed to demonstrate
clinical benefit with routine use of counterpulsation in differ-
ent clinical settings such as high-risk PCI, ST elevation myo-
cardial infarction and cardiogenic shock [5–7]. However,
across all of these trials, a significant minority of patients in
the control arms have become compromised during the course
of PCI and required bailout IABC insertion. Despite the un-
certainty introduced by patient crossover from the conserva-
tive arms of these trials, there has been a downgrading of the
recommendations for use in international guidelines [8], with
a gradual decline in usage noted in recently published regis-
tries [9]. However, IABC still remains to be the most widely
available circulatory support device in cardiac catheterisation
laboratories internationally, due to its familiarity, ease of in-
sertion and low cost.
The concept of IABC response has emerged from several
clinical studies and registries from as early as the late 70s,
suggesting that there is a cohort of patients that have a greater
haemodynamic response to balloon counterpulsation [10–13],
which may contribute to the lack of benefit seen in published
RCTs. All of these studies have described response in terms of
broad systemic haemodynamics such as cardiac index, dia-
stolic pressure augmentation and pulmonary capillary wedge
pressure. To date, there has been no characterisation of re-
sponse to IABC therapy in terms of coronary haemodynamics
with pan cardiac cycle or wave intensity analysis (WIA) pa-
rameters. CoronaryWIA through the simultaneous acquisition
of distal coronary pressure and flow has allowed researchers
to understand the intricate interaction between the myocardi-
um and coronary circulation in various different pathological
states [14–16] and is a tool that has been used to understand
the coronary effects of IABC therapy [1].
The main aims of this study were to comprehensively in-
vestigate the effects of balloon counterpulsation on invasive
coronary and left ventricular (LV) physiology in a cohort of
patients undergoing high-risk PCI, to investigate the impact of
counterpulsation on cardiac coronary coupling through
coronary wave intensity analysis and to define responders
using coronary physiology to further characterise the cohort
of patients most likely to benefit from IABC therapy.
Methods
Patient Population
Patients scheduled to undergo high-risk PCI with intra-aortic
balloon pump support at two tertiary cardiac centres were
eligible for enrolment. Inclusion criteria were an LV ejection
fraction (LVEF) < 40%, complex coronary anatomy (left main
stem, multi-vessel disease, bifurcation disease, the presence of
coronary calcification) and extensive coronary disease (British
Cardiovascular Intervention Society (BCIS) jeopardy score
(JS) ≥ 6 [17]). Exclusion criteria were severe peripheral vas-
cular disease precluding insertion of the IABP, cardiogenic
shock or peri-procedural haemodynamic instability.
Catheter Laboratory Protocol
All patients were preloaded with 300 mg of aspirin and
600 mg of clopidogrel. Three arterial sheaths were inserted
under local anaesthetic: one in the radial artery (6F, for the
guiding catheter) and one in each femoral artery (8F (for the
LV conductance catheter where performed) and 9F (for the
IABC device) sheaths respectively). Heparin was adminis-
tered as standard for PCI procedures. An IABP catheter
(Maquet, either 40 cc or MEGA 50 cc according to patient
height) was inserted into the descending aorta distal to the
subclavian artery origin and was activated with a
counterpulsation ratio of 1:1. After PCI was completed, hae-
modynamic measurements were obtained in the aorta, target
coronary artery and within the left ventricle. A 0.014″ dual
pressure and Doppler flow guidewire (ComboWire XT,
Philips) was inserted into the target coronary vessel through
a fluid-filled guide catheter following pressure calibration.
The coronary Doppler signal was optimised through manual
adjustments of the wire tip within the vessel under fluoroscop-
ic guidance. Following this in a subset of patients, an LV
conductance catheter (CD Leycom, Zoetermeer, the
Netherlands) was inserted into the LV along its longitudinal
axis (see Fig. 1a). The catheter was connected to a signal
conditioning and processing console, for real-time acquisition
and display of pressure volume loops (see Fig. 1b). The con-
ductance catheter technique has been previously described
[18, 19]. This system allows the simultaneous acquisition of
ventricular pressure and volume through a single pressure
sensor and 12 evenly spaced electrodes on the pigtail catheter
that measure time-varying segmental conductance. Volume
correction was performed off-line post data acquisition, using
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3D echocardiographic volumes obtained pre-PCI on day of
the study protocol.
Following Doppler signal and LV pressure volume loop
optimisation, measurements were obtained during 1:1
counterpulsation and with the balloon pump on standby, en-
suring that heart rate, blood pressure and coronary average
peak velocity had returned to baseline prior to a change in
experimental condition (see Fig. 1c for representative
coronary Doppler f low signals acqui red dur ing
counterpulsation).
Data Analysis
Coronary and Aortic Haemodynamic Data
Coronary data were sampled at 200 Hz and exported into
dedicated software (Study Manager, Academic Medical
Center, University of Amsterdam, Netherlands). A minimum
of ten beats were selected for off-line analysis using custom-
made software (CardiacWaves, King’s College London, UK).
Ensemble averages of at least five selected cardiac cycles were
analysed with a Savitzky-Golay convolution method for
smoothing of the mean aortic (Pa) and coronary average peak
velocity (APV) signals.
Pulse wave analysis was performed on central aortic
pressure wave forms, with the calculation of the tension
time index (TTI, area under the systolic portion of the
aortic pressure wave form), the diastolic time index (DTI,
area under the diastolic portion) and the Buckberg index
(BI, index of myocardial supply and demand calculated as
the ratio between DTI to TTI) [20]. Rate pressure product
(RPP) was calculated by multiplying the heart rate by the
systolic blood pressure (SBP). Diastolic augmentation was
calculated as the augmented diastolic pressure during
IABC minus unassisted diastolic aortic pressure. Systolic
unloading was calculated as the unassisted SBP minus the
SBP during IABC. Coronary microvascular resistance was
calculated as mean Pd divided by APV.
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Fig. 1 Study haemodynamic data
acquisition. a Fluoroscopic
placement of IABP catheter in the
descending aorta, with
ComboWire (CW) visualised in
the left anterior descending artery
and a PV loop catheter (CC) in the
LV. b Representative PV loop
obtained with and without IABC
support. c Representative
coronary data acquisition with the
ComboWire and IABC support at
1:2 (red: aortic pressure, yellow:
distal coronary pressure, blue:
flow velocity (Doppler) trace)
Coronary wave intensity analysis was performed as previ-
ously described [15, 21]. In summary, net wave intensity (δI)
was calculated from the time derivatives (δt) of the ensemble
averaged distal coronary pressure (Pd) and flow velocity (U),
calculated as follows: δI = δPd / δt × δU / δt. The aortic-derived
and microcirculatory-derived waves were separated assuming
a blood density of 1050 kg m−3 and estimating a coronary
wave speed using the sum of squares method [22]. The peak
intensity of the four main waves was calculated (aortic-de-
rived acceleratory forward compression wave (FCW), the
microcirculatory-derived decceleratory backward compres-
sion wave (BCW), the aortic-derived decceleratory forward
expansion wave (FEW) and the microcirculatory-derived
backward expansion wave (BEW), considered to be the main
contributor of coronary perfusion [15]). During IABC therapy,
two further waves were identified as previously described, the
IABP-FCW (acceleratory associated with balloon inflation)
and the IABP-FEW (decceleratory wave) [1]. Perfusion effi-
ciency (PE) was calculated as the percentage of accelerating
waves of the total wave energy, using the area under the curve
for each wave [16, 23]. For the calculation of PE during bal-
loon counterpulsation, the IABP-forward compression wave
(IABP-FCW) and IABP-forward expansion wave (IABP-
FEW) were added to the total acceleratory and decceleratory
wave energies respectively.
LV Haemodynamic Data
LV haemodynamic data was extracted and imported into
custom-made software (Simplewires, King’s College
London, UK) following the application of a 25-Hz filter for
off-line analysis. At least ten consecutive cycles were selected
from each condition, with the ensemble average of at least five
beats within the sample used for data analysis. Left ventricular
conductance volumes (EDV and ESV) were calculated at the
maximum rate of pressure rise during systole (dP/dTmax) and
pressure decay during diastole (dP/dTmin). Stroke volume was
calculated as EDVminus ESV. LV stroke work was calculated
as the area within the pressure volume loop. Pressure volume
area (PVA), which is a measure of total mechanical energy
generated by ventricular contraction, was calculated as the
sum of stroke work and potential energy as previously de-
scribed [24]. A myocardial supply/demand ratio was calculat-
ed as the ratio between coronary APVand PVA.
Classification of Coronary Responders
Coronary responders were defined as those patients that had
an increase in coronary PE during IABC therapy. PCI was
classed dichotomously as complex or not on the basis of lesion
characteristics, contrast volume and use of adjunctive devices
such as rotational atherectomy.
Statistical Analysis
Statistical analysis was performed using IBM SPSS Version
24. Normality was assessed qualitatively through the review
of histograms and quantitatively with the Shapiro-Wilk test.
Normally distributed data is presented asmean ± SD, and non-
normally distributed data is presented as median (interquartile
range). Normally distributed data were compared using paired
t tests, and non-normally distributed data were compared with
the Mann-Whitney U test. Categorical data was compared
with the chi-squared test. A p value of < 0.05 was considered
significant. Correlation analysis was performedwith the use of
the Pearson correlation coefficient.
Ethical Conduct and Approval Statement
All procedures followed were in accordance with the ethical
standards of the responsible committee on human experimen-
tation (UK National Health Service Research Ethics Service,
Research Ethics Committee London Bridge, reference 11/
H0804/10) and with the Helsinki Declaration of 1975, as re-
vised in 2000. Informed written and verbal consent was ob-
tained from all patients enrolled into the study.
Results
Patient and Procedural Characteristics
Thirty-six patients were enrolled, but nine were excluded due
to haemodynamic instability during the procedure or vascular
access difficulties. Twenty-seven patients (age 70 ± 9 years,
89% male, LVEF 31% ± 9%, JS 10 ± 2) underwent coronary
assessment during device support. The last nine patients en-
rolled also underwent LV haemodynamic assessment, follow-
ing successful approval of a substantial amendment to the
local ethics committee. A 40-cc intra-aortic balloon pump
catheter was used in 81% of cases and a 50-cc catheter in
the others. Overall, there was no in-hospital mortality, and
event rates were low.
Effect of IABC on Systemic, Coronary and Left
Ventricular Haemodynamics
IABC resulted in systolic unloading and diastolic augmenta-
tion (see Table 1), with a significant reduction in rate pressure
product (7857.9 (6270.8, 10,270.23) vs. 6279.0 (5089.0,
8210.6), p = 0.001). There was a numerical increase in mean
arterial pressure with IABC (p = 0.07). Balloon pump activa-
tion resulted in a significant reduction in LVend systolic pres-
sure (109.5 ± 17.7 vs. 88.5 ± 16.5 mmHg, p < 0.001) and a
reduction in LV end diastolic pressure (19.0 ± 10.3 vs. 15.6
± 7.5 mmHg, p = 0.05); see Table 1. There was a significant
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reduction in afterload, as measured by arterial elastance (3.0 ±
1.4 vs. 2.1 ± 0.9 mmHgmL, p = 0.03). However, there was no
difference in LV stroke work or PVAwith balloon activation
(p = 0.77 and p = 0.33 respectively), with no difference in the
myocardial supply/demand ratio (0.0040 ± 0.0046 vs. 0.0049
± 0.0043, p = 0.34).
IABC resulted in an increase in distal coronary pressure
(80.7 ± 14.0 vs. 84.9 ± 26.8 mmHg, p = 0.04), an increase in
coronary flow (APV 27.2 ± 13.5 vs. 33.9 ± 13.6 cm s−1, p =
0.001) and a reduction in coronary microvascular resistance
(2.9 (2.5, 4.6) vs. 2.7 (2.1, 3.4) mmHg cm s−1, p = 0.049); see
Table 2.
During unassisted conditions, the four main previously de-
scribed coronary wave energies were identified in all patients.
During counterpulsation, an acceleratory IABP-FCW was
identified that relates to balloon inflation and a decceleratory
IABP-FEWwave was identified in all patients; see Fig. 2. The
IABP-FCW correlated with the degree of diastolic augmenta-
tion (p < 0.001, R2 = 0.49); see Fig. 3.
Defining Coronary Haemodynamic Responders
There was no significant difference in peak wave intensity for
each of the four waves during unassisted and assisted
Table 1 Aortic and left
ventricular haemodynamic
characteristics
Unassisted Assisted p value
Aortic parameters
HR (beats min−1) 73.5 ± 15.7 71.5 ± 12.9 0.39
SBP (mmHg) 114.4 ± 21.0 98 ± 26.8* < 0.001
DBP (mmHg) 64.4 ± 10.1 127.8 ± 38.7* < 0.001
Pa (mmHg) 83.1 ± 12.1 88.8 ± 23.4 0.07
RPP (mmHg bpm) 7857.9 (6270.8, 10,270.2) 6729.0 (5089.9, 8210.6)* 0.001
DTI 35.6 (30.0, 44.3) 49.7 ± 14.9* < 0.001
ITI 33.7 (26.2, 36.6) 26.3 ± 9.3* < 0.001
BI 1.2 (0.9, 1.4) 2.0 (1.6, 2.3) < 0.001
LV haemodynamics
EDP (mmHg) 19.0 ± 10.3 15.6 ± 7.5 0.05
ESP (mmHg) 109.5 ± 17.6 88.5 ± 16.5* < 0.001
SV (mL) 40.9 (32.9, 46.8) 46.4 (29.4, 55.9) 0.09
dP/dt+ (mmHg s−1) 862.3 ± 90.2 788.8 ± 117.5* 0.03
dP/dt− (mmHg s−1) − 873.9 ± 119.1 − 710.5 ± 110.0* 0.001
CO (L min−1) 3.0 (1.7, 3.4) 3.3 (2.1, 4.5) 0.14
SW (mmHg mL) 3676.4 (2683.5, 4565.5) 3562.4 (2292.2, 4144.8) 0.77
PVA 10,967.4 ± 7711.7 10,042.3 ± 6826.9 0.33
Arterial elastance (mmHg mL−1) 3.0 ± 1.4 2.1 ± 0.89 0.003
*p < 0.05 unassisted vs assisted
Table 2 Coronary haemodynamic characteristics
Unassisted Assisted p value
Coronary pan cardiac cycle indices
Pd (mmHg) 80.7 ± 14.1 84.9 ± 18.2* 0.04
APV (cm s−1) 27.2 ± 13.5 33.9 ± 17.6* 0.001
MR (mmHg cm s−1) 2.9 (2.5, 4.6) 2.7 (2.1, 3.4)* 0.049
Coronary WIA (W m−2 s−2 × 105)
FCW 0.62 (0.37, 0.89) 0.67 (0.33, 1.57) 0.19
BCW − 0.59 (− 0.78, − 0.24) − 0.65 (− 0.98, − 0.29) 0.39
FEW 0.17 (0.04, 0.38) 0.12 (0.04, 0.28) 0.47
BEW − 1.28 (− 1.81, − 0.93) − 1.20 (− 3.10, − 0.81) 0.29
IABP-FCW n/a 1.42 (0.77, 2.09) n/a
Perfusion efficiency 79.0 (65.8, 86.4) 73.7 (69.2, 83.2) 0.77
*p < 0.05 unassisted vs assisted
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conditions (see Table 2 for mean peak wave energies). IABC
therapy had a variable impact on perfusion efficiency, which
ranged between − 36.2% and 100.3% across the cohort. Of
patients, 44.4% had an increase in perfusion efficiency with
IABC and were classed as coronary responders. There was no
significant difference in demographics between non-
responders and responders (see Table 3). Coronary responders
were more likely to have a greater extent of coronary disease
(BCIS JS 9.1 ± 2.5 vs. 11 ± 1.3, p = 0.02) and to have under-
gone more complex (p = 0.03) and multi-vessel PCI (p =
0.04).
There was no significant difference in the degree of diastol-
ic augmentation or systolic unloading (see Table 4).
Responders had a lower distal coronary pressure (88.0 ± 11.0
vs. 71.6 ± 12.4 mmHg, p < 0.001) and mean aortic pressure
(87.4 ± 11.0 vs. 77.8 ± 11.6 mmHg, p = 0.04) during unassist-
ed conditions. There was no difference in unassisted micro-
vascular resistance (3.19 (2.56, 4.51) vs. 2.51 (1.98, 5.08)
mmHg cm s−1, p = 0.37) or coronary flow between groups
(27.2 ± 11.0 vs. 27.2 ± 16.1 cm s−1, p = 1). The percentage
change in PE negatively correlated with the distal coronary
pressure (R2 = 0.48, p < 0.001, see Fig. 4) and diastolic blood
pressure (R2 = 0.36, p < 0.001) during unassisted conditions.
In the nine patients with paired coronary and LV haemody-
namic data, there were no differences between responders or
non-responders in LVend systolic pressure, LVEDP, ventricular
volumes or arterial elastance. There was no difference in LV
stroke work (4084.2 ± 1015.9 vs. 4414.14160.6 mmHg mL,
p = 0.9) or PVA (10,241.2 ± 6211.9 vs. 11,548.3 ±
9436.6 mmHg mL, p = 0.8). Numerically, there was a decline
in PVAwith IABC therapy in responders, which did not reach
statistical significance (delta PVA 591.9 ± 2833.3 vs. − 2138.7
± 2077.9 mmHg mL, p = 0.14).
Discussion
The following are the main findings of this study:
1. The effects of IABC on supply are more marked than
those on demand, with a neutral effect seen on the myo-
cardial supply/demand ratio.
2. There is marked variability in coronary response to IABC
as demonstrated by the range in change in perfusion effi-
ciency, with less than half of the patients classed as
responders.
3. Coronary responders were more likely to have a higher
burden of coronary disease, to have undergonemore com-
plex PCI and to have lower unassisted aortic and distal
coronary pressures following PCI.
Intra-aortic balloon pump counterpulsation has been the
staple percutaneous haemodynamic support device for more
than 40 years [25] and up until recently the only device avail-
able to the interventional cardiologist for haemodynamic sup-
port. We are currently in an era where increasing aged patients
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Fig. 2 Representative WIA profile during unassisted (a) and assisted (b)
conditions. The four main coronary waves are depicted (FCW forward
compression, BCW backward compression wave, FEW forward
expansion wave, BEW backward expansion wave). In b, the two IABP
balloon inflation and deflation related waves are depicted (IABP-FCW
IABP-forward compression wave, IABP-FEW IABP-forward expansion
wave)
Fig. 3 IABP relationship with diastolic augmentation. During IABC, the
IABP-FCW is linearly correlated with the degree of diastolic aortic pres-
sure augmentation
undergo PCI, and inevitably, they have a higher burden of co-
morbidities, including prior AMI and impaired LV function.
This poses a significant challenge, as it is known that the
presence of LV dysfunction increases mortality following
PCI [26]. Research has therefore been focused on strategies
to reduce the ischaemic burden and subsequent complications,
via a positive impact on the myocardial supply/demand ratio.
Despite its ease of use, availability and extensive favourable
physiology and registry data, IABC deployment is declining
due to the publication of several neutral randomised trials that
have all concluded that routine use of IABC therapy in various
clinical settings does not alter outcomes [5–7]. However, there
is a consistent subset of patients in the control arms of each of
the studies that required bail out therapy, suggesting a group
that may benefit. It is these patients that need to be identified,
through the investigation of clinical characteristics and of pre-
dictors of response. There are clinical situations emerging
where the use of IABC therapy may be beneficial. Van
Nunen et al. studied a subgroup of patients from the CRISP-
AMI trial, who had a large anterior MI and persistent ischae-
mia as defined by poor ST segment resolution [27]. In this
group, IABC reduced 6-month mortality and there was a re-
duction in the composite end point. Despite the limitations of a
small sample size and the fact that this study was a subgroup
analysis of a larger clinical trial, the data is hypothesis gener-
ating and suggests a clinical cohort who may benefit.
The physiological effects of IABC have been extensively
studied, both in animal models and clinical studies. These
studies have confirmed the balloon pump’s effect on aortic
haemodynamics, with diastolic augmentation and systolic
unloading being its predominant effects. Previous studies on
the effects of IABC on coronary flow have demonstrated that
it is in those that have more deranged haemodynamics [3] or
evidence of disabled autoregulation following administration
of adenosine [1] that there is an observed augmentation in
coronary flow with counterpulsation, eluding to a variability
in haemodynamic response to IABP therapy between patients.
In the current study, we demonstrated that IABC augments
coronary flow without the administration of adenosine. The
difference in our results compared with our group’s previous
work may reflect the type of patients included. The LVEF on
average in this study was 31%, whereas in our group’s previ-
ous work, the average EF was 34%. The patients enrolled in
our study also had a higher BCIS jeopardy score, suggesting a
group overall that have a larger amount of myocardium at risk
and therefore at baseline may have had disordered autoregu-
lation. This study has also begun to unravel the effects of
IABC on coronary wave intensity analysis, with the observa-
tion that the degree of diastolic augmentation correlates with
the magnitude of the IABP-FCW. It is important to note that in
our study and in the prior studies discussed, coronary flow
data was obtained following PCI, once the stenosis had been
relieved. Previous studies have demonstrated no significant
effect of IABC on distal coronary flow velocity in patients
with critical coronary artery disease [2, 28], to suggest a dif-
ferential effect of IABC therapy depending on the presence or
Table 3 Patient and procedural characteristics
Whole cohort
n = 27
Non-responders
n = 15
Responders
n = 12
Age (years) 70 ± 9 70.9 ± 7.0 68.9 ± 10.9
Male 24 (89) 14 (93) 12 (86)
Hypertension 20 (74) 13 (87) 7 (58)
Diabetes 11 (41) 7 (47) 4 (33)
Hypercholesterolaemia 22 (81) 14 (93) 8 (67)
History of prior MI 13 (48) 7 (47) 7 (58)
LVEF (%) 31 ± 9 31.3 ± 8.4 30.3 (10.6)
BCIS-JS 10 ± 2 9.1 ± 2.5 11 ± 1.3Λ
Number of stents 1.9 ± 0.9 1.8 ± 1.0 2.1 ± 0.8
Multi-vessel PCI 8 (30) 3 (20) 7 (58)Λ
Rotational atherectomy 1 (4) 0 (0) 1 (8)
Procedural time (min) 106 ± 27 102.9 ± 22.3 109.8 ± 31.2
In-hospital mortality 0 (0) 0 (0) 0 (0)
Peri-procedural inotropes/vasopressors 0 (0) 0 (0) 0 (0)
Post PCI complications 2 (7) 1* (7) 1** (8)
Data are mean ± SD or n (%)
*No reflow post PCI
**Atrial fibrillation post procedure and cerebral embolus in the same patientc
Λ p < 0.05 non-responders versus responders
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absence of a stenosis. In the study by Kern et al. [2], it was
only following PCI that an augmentation of coronary flow
was observed with IABC. In this present study, we were un-
able to obtain coronary physiology data prior to PCI, and
therefore, the physiological effects seen are with an open cor-
onary artery free of significant disease.
In this study, we have demonstrated that the effects of
counterpulsation are less pronounced on the left ventricle than
those on the coronary circulation with no effects observed on
stroke work or pressure volume area, with a resultant neutral
effect of IABC on the myocardial supply and demand ratio.
Previous animal [29, 30] and clinical studies [11] have not
demonstrated consistent effects on stroke work and pressure
volume area, but these studies present a variety of different
heart failure models and different patient cohorts. Whether the
current results explain why in particular patients in cardiogen-
ic shock have not been shown to derive a clinical benefit
(where there is a predominant myocardial issue), alongside
its overall modest effect on cardiac output and mean arterial
pressure, needs to be evaluated further. It may be that devices
that off load the LV such as the Impella device may have more
significant effects on reducing myocardial demand.
Previous studies have defined IABP responders as those
patients who have a significant systemic haemodynamic effect
from counterpulsation, whether it be the degree of augmenta-
tion of cardiac index, reduction of pulmonary capillary wedge
Table 4 Coronary responder and
non-responder haemodynamics Non-responders n = 15 Responders n = 12 p value
Aortic parameters
Diastolic augmentation (mmHg*) 65.1 ± 39.0 61.2 ± 34.4 0.8
Systolic unloading (mmHg*) 12.7 ± 17.7 20.9 ± 12.0 0.19
Pa (mmHg) 87.4 ± 11.0 77.8 ± 11.6 0.04*
RPP (mmHg bpm) 88,978.7 ± 2809.8 7722.2 ± 1605.8 0.18
BI 1.1 ± 0.41 1.3 ± 0.3 0.18
Coronary pan cardiac cycle indices
Pd (mmHg) 88.0 ± 11.0 71.6 ± 12.4 < 0.001*
APV (cm s−1) 27.2 ± 11.8 27.2 ± 16.1 1.00
MR (mmHg cm s−1) 3.2 (2.5, 4.5) 2.5 (2.0, 5.1) 0.9
Coronary WIA (W m−2 s−2 × 105)
FCW 0.74 ± 0.42 0.58 ± 0.46 0.35
BCW − 0.49 ± 0.24 − 0.83 ± 0.64 0.07
FEW 0.12 ± 0.15 0.45 ± 0.37 < 0.001*
BEW − 1.8 ± 1.2 − 1.3 ± 0.9 0.22
IABP-FCW* 1.4 ± 1.2 2.3 ± 2.3 0.21
Perfusion efficiency (%) 62.6 ± 16.7 < 0.001*
LV haemodynamics
EDP (mmHg) 20.6 ± 13.5 17.8 ± 8.4 0.70
ESP (mmHg) 111.4 ± 13.9 108.0 ± 21.8 0.80
SV (mL) 42.0 ± 5.3 50.1 ± 44.8 0.70
SW (mmHg mL) 4084.2 ± 1015.9 4414.1 ± 4160.6 0.90
PVA (mmHg mL) 10,241.2 ± 6211.9 11,548.3 ± 9436.6 0.80
Arterial elastance (mmHg mL−1) 2.7 ± 0.3 3.3 ± 1.9 0.50
All data presented was obtained during unassisted conditions apart from those haemodynamic parameters
annotaed with *
*p < 0.05 non-responders versus responders
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Fig. 4 Relationship between distal coronary pressure during unassisted
conditions and percentage change in perfusion efficiency with IABC
therapy. The lower the distal coronary pressure, the greater the
increment in perfusion efficiency with IABC
pressure or effects on other haemodynamic indices such as left
and right heart filling pressures. A clinical study of 76 patients
undergoing IABP therapy with a 50-cc balloon pump defined
responders as those that had a higher cardiac output after
IABP insertion (n = 60) and those that did not (n = 16) [31].
They found that the best predictor of response was having a
baseline cardiac index of 0.3 or less, but no difference in
hospital mortality was observed between groups. An invasive
LV pressure volume loop study in patients with advanced
heart failure also tried to address the issue of response [11],
defining response according to the degree of increment in
cardiac index above the median for the group. They observed
that overall, patients defined as responders had lower right-
sided filling pressures and higher systemic vascular resistance.
In this study, responders were defined on the basis of IABC
effects on coronary haemodynamics, the first to date to define
responders in this way. There was an observed large range of
change in perfusion efficiency with IABC, which again is
reflective of the clinical heterogeneity despite using broad
diagnostic criteria to enrol these patients into the study. We
found that responders had a higher BCIS jeopardy score and
were more likely to have undergone complex multi-vessel
PCI. We also found that responders had lower mean distal
coronary and aortic pressures during basal conditions, with
both demonstrating a negative correlation with percentage
change in perfusion efficiencywith IABC. These observations
further add to the body of evidence emerging that it is in those
patients that have worse coronary haemodynamics at the out-
set (with worse perfusion efficiency and exhausted autoregu-
lation), a larger ischaemic burden, and that undergo more
complex PCI are those that are more likely to respond physi-
ologically to IABC therapy. There were no obvious
differentiators in terms of LV haemodynamics, but this may
be in part related to the small sample size of patients undergo-
ing paired coronary and LV haemodynamic assessment.
Further studies need to be performed that enrol patients with
more narrowly defined physiological parameters to under-
stand the effect of IABC on clinical outcomes.
Limitations
This is a small physiological study and may be prone to
type 1 error due to the small sample size. However, this is
the largest invasive study to date on balloon pump coro-
nary and LV physiology. As mentioned above, all mea-
surements were obtained post PCI, and we therefore may
not be able to translate these results to those patients with
untreated severe coronary artery disease. Measurements
were also taken in clinically stable patients, which is
reflected by our low event rates. It is likely that the phys-
iology of IABC is different in patients with haemodynam-
ic instability or cardiogenic shock, again limiting the
translatability of our observations The use of perfusion
efficiency as a means to define responders is not clinically
applicable, due to its invasive nature and reliance of good
coronary Doppler signals to perform WIA; however, it has
allowed us to begin to understand which patients may
der ive a g rea te r bene f i t in t e rms of corona ry
haemodynamics.
Conclusion
This is the largest invasive clinical study to date of balloon
counterpulsation, reaffirming its significant effects on the cor-
onary circulation, with an augmentation in coronary flow ob-
served regardless of the autoregulatory state. The effects on
LV haemodynamics are less pronounced. IABP responders in
this cohort as defined by the change in perfusion efficiency
weremore likely to have disordered autoregulationwith worse
systemic haemodynamics, lower distal coronary pressure, and
were more likely to have a higher ischaemic burden and to
have undergone complex PCI.
Clinical Implications
The use of IABC has been questioned, and use is on the
decline. This study highlights the heterogeneous physiological
response to IABC therapy despite using the same broad clin-
ical criteria to select patients for enrolment, which may ex-
plain the lack of benefit seen in large randomised controlled
trials. The findings that in those patients with the most de-
ranged haemodynamics following PCI have a greater coro-
nary response may aid the design of future clinical trials to
establish patient cohorts that may derive benefit, to ultimately
aid clinicians in selecting patients for IABC therapy.
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